| David O'connor, MD | |
|
2815 S Seacrest Blvd, Boynton Beach, FL 33435-7934 | |
| (561) 736-1200 | |
| (561) 742-1919 |
| Full Name | David O'connor |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 2815 S Seacrest Blvd, Boynton Beach, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801860655 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | ME0076535 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bethesda Hospital Inc | Boynton beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elite Imaging Llc | 2466496880 | 108 |
| Baptist Outpatient Services Inc | 6002807385 | 148 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Radiology Associates Of South Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699759183 PECOS PAC ID: 5799689659 Enrollment ID: O20031121000573 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Bethesda-ct Scan Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376588731 PECOS PAC ID: 4284521071 Enrollment ID: O20040304000725 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Baptist Outpatient Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437127529 PECOS PAC ID: 6002807385 Enrollment ID: O20040527000618 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20040714001317 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Elite Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346516853 PECOS PAC ID: 2466496880 Enrollment ID: O20050616000704 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Tampa Bay Radiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518914977 PECOS PAC ID: 1456381136 Enrollment ID: O20050813000096 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Sheridan Radiology Services Of Pinellas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083007454 PECOS PAC ID: 7517119407 Enrollment ID: O20121128000124 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | F&s Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518299957 PECOS PAC ID: 0244368868 Enrollment ID: O20140731002204 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Entity Name | Radiology Physician Solutions Of North Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447761101 PECOS PAC ID: 2466710306 Enrollment ID: O20180216001493 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David O'connor, MD 200 Knuth Rd, Suite 200, Boynton Beach, FL 33436-4629 Ph: (561) 736-1200 | David O'connor, MD 2815 S Seacrest Blvd, Boynton Beach, FL 33435-7934 Ph: (561) 736-1200 |
News Archive
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
Toshiba Corporation has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses.
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could decrease the chances they'll be readmitted.
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
› Verified 1 days ago
Alfred Sem, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 | |
Dr. David Dahlenburg, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2815 S Seacrest Blvd, Boynton Beach, FL 33435 Phone: 561-737-7733 | |
Dr. Valerie D'aurora, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S. Seacrest Blvd, Boynton Beach, FL 33435 Phone: 551-208-6680 | |
Carol Ann Vicinanza Adami, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 | |
Fred Tow, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 8921 Raven Rock Ct, Boynton Beach, FL 33473 Phone: 941-356-2266 | |
Ariana Alvarez, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 | |
Richard Edelstein, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 |